These Vanguard Funds Have Been Hot, But Is It Time to Cool Off on Buying Them?The Motley Fool • 02/15/24
Vergent Bioscience Presents Phase 2 Data Showing VGT-309 Visualizes Tumors in the Lung During SurgeryBusiness Wire • 01/28/24
Vergent Bioscience to Present New Efficacy Results from Phase 2 Clinical Trial of VGT-309 at Annual Meeting of The Society of Thoracic SurgeonsBusiness Wire • 01/17/24
ETFs In Focus as Microsoft Tops Apple as Most Valuable Public CompanyZacks Investment Research • 01/15/24